Europe Frontotemporal Dementia Market to Witness Significant Growth until 2025
Increasing funding by
government for R&D activities and rising life expectancy rate to drive
Europe frontotemporal dementia market
According
to TechSci Research report, “Europe Frontotemporal Dementia Market By Drug Class Type
(Antidepressants (Fluoxetine, Fluvoxamine, Sertraline, Paroxetine, Citalopram,
Bupropion, Mitrazepine), Antipsychotics (Olanzepine, Quetiapine, Ziprasidone,
Aripiprazole, Risperidone, Paliperidone), By Disease Type (Behavior Variant
Frontotemporal Dementia (bvFTD), Primary Progressive Aphasia (PPA), Others), By
Distribution Channel (Hospital Pharmacy, Retail Pharmacy, Drug Store, Online
Pharmacy, Others), By End User (Hospitals, Specialty Clinics, Others), By Country,
Forecast & Opportunities, 2025”, the market is expected to undergo a formidable rate of
growth during the forecast period owing to the focus of European nations towards
providing best healthcare facilities to the population. Governments are also
increasing funding for research and development activities to find the best
treatment for neurological diseases such as frontotemporal dementia. Moreover, growing
geriatric population, which is more prone to frontotemporal dementia, is also
acting as a major factor behind the growth of this market in Europe. Moreover,
the increasing life expectancy rate is expected to support the growth of Europe
frontotemporal dementia market until 2025.
Additionally, various non-profit organizations are
also providing financial aid and funding for drug development, which is acting
as a major boost for the growth of this market. Extensive clinical trials to
find the best treatment for frontotemporal dementia is further aiding the
growth of the market. The availability of advanced care of treatments such as
mental treatment centers and home care administrations in Europe is making the
region a favorable market for the companies dealing in frontotemporal dementia.
However, the market also faces some major challenges.
Lack of approved drugs and high chances of misunderstanding with Alzheimer’s
disease might act as a restraint for the growth of Europe frontotemporal
dementia market.
Browse
XX market data Tables and XX Figures spread through XXX
Pages and an in-depth TOC on "Europe Frontotemporal Dementia Market"
https://www.techsciresearch.com/report/europe-frontotemporal-dementia-market/4859.html
The Europe
frontotemporal dementia market is segmented based on drug class type, disease
type, distribution channel, end user and region. Based on disease type, the Europe
frontotemporal dementia market is categorized into Behavior Variant
Frontotemporal Dementia (bvFTD), Primary Progressive Aphasia (PPA) and others. Among
them, the Behavior Variant Frontotemporal Dementia segment is highly prevalent
in Europe and this is why the segment is
expected to undergo rapid growth during the forecast period. Some common symptoms
of behavior variant frontotemporal dementia include behavioral changes, apathy
and changes in stereotypic behavior.
Based
on drug class type, Europe frontotemporal dementia market is categorized into antidepressants
and antipsychotics. Here, the antidepressant segment is poised to witness
highest growth during the forecast period owing to their extensive use to
minimize behavioral problems associated with frontotemporal dementia. Moreover,
medical experts are also recommending antidepressants to manage the health of
the patient which is acting as a major reason behind the growing demand for antidepressant
drugs.
Major players operating in the Europe frontotemporal
dementia market include GlaxoSmithKline PLC, Eli Lilly Italia - S.P.A., Pfizer
Deutschland GmbH., F. Hoffmann-La Roche Ltd., Novartis AG, AstraZeneca GmbH,
Sanofi S.A, Allergen plc, Johnson & Johnson and Mylan Dura GmbH. Leading
market players are also investing on clinical studies and trials for new drug
developments.
Download
Sample Report @ https://www.techsciresearch.com/sample-report.aspx?cid=4859
Customers
can also request for 10% free customization on this report.
“According
to the latest report by Dementia Statistics Organization, the number of people
living with dementia is expected to increase to 152 million by 2025 around the
world. The cases will certainly rise in Europe, which is witnessing surge in
geriatric population. This is expected to propel the growth of frontotemporal
dementia market in the region. With more manufacturers entering the market, the
market is anticipated to grow further until 2025,” said Mr. Karan Chechi,
Research Director with TechSci Research, a research based global management
consulting firm.
“Europe Frontotemporal Dementia Market By Drug Class
Type (Antidepressants (Fluoxetine, Fluvoxamine, Sertraline, Paroxetine,
Citalopram, Bupropion, Mitrazepine), Antipsychotics (Olanzepine, Quetiapine,
Ziprasidone, Aripiprazole, Risperidone, Paliperidone), By Disease Type
(Behavior Variant Frontotemporal Dementia (bvFTD), Primary Progressive Aphasia
(PPA), Others), By Distribution Channel (Hospital Pharmacy, Retail Pharmacy,
Drug Store, Online Pharmacy, Others), By End User (Hospitals, Specialty
Clinics, Others), By Country, Forecast & Opportunities, 2025” has evaluated the future growth potential of Europe frontotemporal
dementia market and provides statistics & information on market size,
structure and future market growth. The report intends to provide cutting-edge
market intelligence and help decision makers take sound investment decisions. Besides,
the report also identifies and analyzes the emerging trends along with
essential drivers, challenges and opportunities in Europe frontotemporal
dementia market.
Contact
Mr. Ken Mathews
708 Third Avenue,
Manhattan, NY,
New York – 10017
Tel: +1-646-360-1656
Email: [email protected]